We work hand-in-hand with carefully chosen partners to commercialize our products and to ensure supply and access for the people who need them.
Samsung Bioepis has an extensive global marketing and sales network through our commercialization partnerships with Biogen and Organon. Biogen is a biotechnical pioneer with over 40 years of experience of developing, manufacturing and commercializing advanced biologic medicines, that is underpinned by a reliable supply chain record. Organon, a global healthcare company formed through a spinoff from Merck (known as MSD outside of the U.S. and Canada), works with customers and operate in more than 140 countries to increase patient access to treatments. Through partnerships, our rapidly growing biosimilar business is expanding into multiple markets across the world including China, where we are working with local partners 3SBio and C-Bridge Capital for clinical development, regulatory registration, and commercialization of our products. As part of our long-term vision, we have entered into a risk-sharing partnership with Takeda to begin development of a number of novel biologics.
We supply our products in a timely manner by working with Contract Manufacturing Organizations (CMOs) that have extensive experience in manufacturing. We manage manufacturing and storage sites across Europe, North America and Asia to ensure supply continuity for patients.